US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Viatris Inc. - Common Stock
(NQ:
VTRS
)
19.04
-0.16 (-0.86%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Viatris Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
VIATRIS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS
May 08, 2025
From
SkyMedia, LLC
Via
GlobeNewswire
These S&P500 stocks that are showing activity before the opening bell on Thursday.
↗
May 08, 2025
Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday?
Via
Chartmill
Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday
↗
May 08, 2025
Via
Benzinga
Earnings Scheduled For May 8, 2025
↗
May 08, 2025
Via
Benzinga
Viatris (NASDAQ:VTRS) Reports Sales Below Analyst Estimates In Q1 Earnings, But Stock Soars 8%
May 08, 2025
Medication company Viatris (NASDAQ:VTRS) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. The company’s full-year revenue guidance...
Via
StockStory
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Viatris, Bakkt, and Cerevel and Encourages Investors to Contact the Firm
May 07, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Top gainers and losers in the S&P500 index during Wednesday's after-hours session.
↗
May 07, 2025
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.
Via
Chartmill
Wall Street Mixed Ahead Of Fed Meeting, Alphabet Sinks: What's Driving Markets Wednesday?
↗
May 07, 2025
U.S. stocks traded mixed at midday Wednesday, as investors remained cautious ahead of the Federal Reserve’s upcoming policy decision, with Chair Jerome Powell set to speak at 2:30 p.m. ET.
Via
Benzinga
Topics
Economy
Viatris Earnings: What To Look For From VTRS
May 07, 2025
Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow morning. Here’s what you need to know.
Via
StockStory
Topics
Artificial Intelligence
VIATRIS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS
May 06, 2025
From
Kahn Swick & Foti, LLC
Via
GlobeNewswire
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
↗
May 06, 2025
Via
Benzinga
SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Viatris Inc. (NASDAQ: VTRS)
May 05, 2025
From
Bernstein Liebhard LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS
May 05, 2025
From
Pomerantz LLP
Via
GlobeNewswire
2 S&P 500 Stocks Worth Investigating and 1 to Avoid
May 05, 2025
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...
Via
StockStory
Topics
Stocks
ROSEN, LEADING INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTRS
May 04, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTRS
May 01, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
VIATRIS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS
May 01, 2025
From
SkyMedia, LLC
Via
GlobeNewswire
VIATRIS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS
April 29, 2025
From
Kahn Swick & Foti, LLC
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS
April 29, 2025
From
Pomerantz LLP
Via
GlobeNewswire
VTRS Investors Have the Opportunity to Lead the Viatris Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
April 29, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Viatris, Canopy Growth, Everus, and BigBear and Encourages Investors to Contact the Firm
April 28, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTRS
April 28, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
VIATRIS INC. (NASDAQ: VTRS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Viatris Inc. Investors of Upcoming Deadline
April 28, 2025
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
April 28, 2025
Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
April 26, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTRS
April 25, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS
April 25, 2025
From
Pomerantz LLP
Via
GlobeNewswire
3 Reasons VTRS is Risky and 1 Stock to Buy Instead
April 24, 2025
Viatris’s stock price has taken a beating over the past six months, shedding 33% of its value and falling to $7.69 per share. This was partly due to its softer quarterly results and might have...
Via
StockStory
VIATRIS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS
April 23, 2025
From
SkyMedia, LLC
Via
GlobeNewswire
VIATRIS SECURITIES FRAUD NOTICE: Berger Montague Informs Viatris (NASDAQ: VTRS) Investors of Securities Fraud Lawsuit
April 23, 2025
From
Berger Montague
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
